Hypercholesterolemia: a literature review on management using tafolecimab: a novel member of PCSK9 monoclonal...

Area of Science:

• Cardiology
• Pharmacology

Background:

• Cardiovascular diseases (CVD) are a leading global cause of mortality, with atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolaemia as major contributors.
• Statins are traditional lipid-lowering drugs, but some patients show intolerance or lack of response, driving the need for novel therapies.
• Tafolecimab is a new PCSK9 monoclonal antibody demonstrating significant LDL-C reduction and a favorable safety profile in clinical trials.

Purpose of the Study:

• To review the role and efficacy of Tafolecimab in managing hypercholesterolaemia.
• To explore Tafolecimab's mechanism of action, clinical trial outcomes, and safety profile.

Main Methods:

• A literature search was conducted using online databases such as PubMed, Scopus, and Embase.
• Articles related to Tafolecimab were identified and reviewed.

Main Results:

• Tafolecimab has shown efficacy in diverse patient populations, including those with comorbidities.
• Ongoing trials (CREDIT-1, CREDIT-2, CREDIT-4) provide insights into its lipid-lowering potential.
• Tafolecimab exhibits greater affinity for PCSK9 and longer LDL-C reduction duration compared to other monoclonal antibodies like evolocumab.

Conclusions:

• Tafolecimab presents a promising therapeutic option for hypercholesterolaemia, especially for specific patient groups.
• Further research is essential to fully understand its long-term impact on cardiovascular outcomes.
• Regulatory evaluation by agencies like the FDA and EMA is necessary.